Benzimidazole derivatives as EP4 antagonists

US9708311B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Olaf Peters · Bad Tabarz, DE
• Nico Bräuer · Falkensee, DE
• Thorsten Blume · Schildow, DE
• Antonius Ter Laak · Berlin, DE
• Ludwig Zorn · Berlin, DE
• Jens Nagel · Daxweiler, DE
• Stefan Kaulfuss · Berlin, DE
• Gernot Langer · Falkensee, DE
• Joachim Kuhnke · Leverkusen, DE

Key dates

• Filing date: Dec 3, 2013
• Grant date: Jul 18, 2017
• Expiry date: Dec 3, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel benzimidazole derivatives of the general formulaprocesses for their preparation and their use for the production of pharmaceutical compositions for the treatment of diseases and indications that are connected with the receptor EP4.